Literature DB >> 475248

Cholesteatoma of the frontal and ethmoid areas.

R S Campanella, D D Caldarelli, S A Friedberg.   

Abstract

Cholesteatomas of the frontoethmoid region must always be considered in the differential diagnosis of a mass in the frontoethmoid region. A painless, slow-growing mass, often accompanied by proptosis and diplopia, but without history of trauma or infection, should make one suspect of this pathologic entity. Although histologically a benign lesion, the keratinizing squamous epithelial lining will continue to desquamate and expand, leading to erosion of surrounding structures which could be life-threatening. In order to prevent recurrence, complete removal of the cyst lining is mandatory. Cosmetic reconstruction, often requiring obliteration of the surgical cavity, should be delayed for one year to insure against recurrence of the covering of active squamous tissue adjacent to dura, cribriform plate or ocular structures.

Entities:  

Mesh:

Year:  1979        PMID: 475248     DOI: 10.1177/000348947908800412

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  4 in total

1.  Frontal bone epidermoid--a rare cause of proptosis.

Authors:  C R Chowdury; C M Wood; P R Samuel; J Richardson
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

2.  Giant intradiploic epidermoid cyst of greater sphenoid wing causing unilateral proptosis and optic nerve compression.

Authors:  E W Sargent; P Garcia; R C Paniello; G J Spector
Journal:  Skull Base Surg       Date:  1993

3.  Nasal sinuses cholesteatoma: case series and review of the English literature.

Authors:  Ahmed Nabil Abdelhamid Ahmed; Mohamed M Elsharnouby; Marwa Mohamed Elbegermy
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-28       Impact factor: 3.236

Review 4.  Differentiating intradiploic orbital dermoid and epidermoid cysts utilizing clinical features and machine learning.

Authors:  Andrea A Tooley; Prashant Tailor; Ann Q Tran; James A Garrity; Laurence Eckel; Michael J Link
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.